Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
Search
Championing for people with all abilities
Every diverse background brings unique perspectives to our company.
Planting Trees to Help Care for the Environment
Planting Trees to Help Care for the Environment
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Employees compassionately help local communities with country-wide food drive
Coming together to bring food to people in need
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Partnering for Innovative Pet Therapeutics
Partnering for Innovative Pet Therapeutics
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
What you need to know about counterfeit medicines
Understand the risk of counterfeit medication.
My journey to advance diversity, equity and inclusion in the workplace
Hear from one of our employees, Tanisha Archer-Parkes, on the importance of diversity in the workplace and continuing to move toward a more inclusive and accepting society.
Boehringer included on LinkedIn’s “Top Companies 2024” list
Investing in our people is at the core of what we do
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
Promising Phase II Results in Chronic Kidney Disease
Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Protecting a Way of Life in Haiti | Boehringer Ingelheim US
Click here to find out how Boehringer Ingelheim is helping to protect a way of life in Haiti by producing a custom swine vaccine to support the island.
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
Occupational Health and Safety
Occupational Health and Safety
BI Cares: Supporting Ukraine
Our family-owned company condemns the ongoing military aggression against Ukraine, and have maintained our support for those in need by providing financial and in-kind donations through our Boehringer Ingelheim Cares Foundation.
BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US
Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim and Vanderbilt University join forces
Boehringer inhalers now available at $35 a month for eligible patients
Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis